Chemotherapeutic profiles of human tumors implanted in SCID mice showing appreciable inconsistencies with those in nude mice.
Sensitivities to antitumor drugs of human tumor xenografts (HTXs) implanted in C.B-17-scid and in BALB/cA-nu were compared to examine whether genetic backgrounds of immune deficiency of the host mice influenced the chemotherapeutic profiles of implanted tumors. In a total of 25 pairs of corresponding experiments with each host mouse strain (5 HTXs x 5 drug treatment groups), we obtained consistent results in 23 (92.0%) experiments consisting of 10 which were both significantly effective and 13 which were both ineffective, although the remaining two (8.0%) experiments showed inconsistent results. A human T-cell lymphoma cell line, LM-2-JCK, implanted in nude mice, was resistant to treatment with 65 mg/kg of cyclophosphamide, but this tumor showed sensitivity to the same treatment when implanted in either SCID mice or mice with a recombination activating gene 2 defect [BALB/cA-TgH (Rag2)], suggesting that the genetic immune background of the host mouse should not be overlooked as a factor affecting tumors.
Yoshimura
M
M
Central Institute for Experimental Animals, Kawasaki, Japan.
Endo
S
S
Hioki
K
K
Ueyama
Y
Y
Ohnishi
Y
Y
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D004351:Drug Resistance; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D008819:Mice, Nude; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D013045:Species Specificity; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D003520:Cyclophosphamide